CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome ...
Yahoo Finance26d
Why CervoMed (CRVO) Is Advancing Today
CervoMed (CRVO) is climbing 3% after Boral Capital upgraded the shares to Buy from Hold. The investment bank placed a $10 price target on the drug maker. Why Boral Upgraded CRVO After meeting with ...
Business Insider6d
JonesTrading Sticks to Its Hold Rating for CervoMed (CRVO)
In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on CervoMed (CRVO – Research Report). The company’s shares opened today at $2.16. Effectively assess a stock's ...
Nasdaq28d
D. Boral Capital Upgrades CervoMed (CRVO)
Fintel reports that on February 19, 2025, D. Boral Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Hold to Buy. As of February 18, 2025, the average one-year price target for ...
Medscape24d
Review of Anti-vascular Endothelial Growth Factor Therapy in Macular Edema Secondary to Central Retinal Vein Occlusions
Recently, an alternative longer acting steroid, dexamethasone implant (Ozurdex), had been extensively studied and gained licensing for its efficacy in treating CRVO-ME. The Ozurdex trial compared ...
Nasdaq14d
Chardan Capital Upgrades CervoMed (CRVO)
Fintel reports that on March 13, 2025, Chardan Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Neutral to Buy. As of March 4, 2025, the average one-year price target for CervoMed ...